For more informationvisit About PerkinElmer Inc

"Cord blood is a valuable, non-controversial sourceof stem cells with proven effect in treating more than 70 serious diseases andwe believe exploring this potential in the treatment of Type 1 diabetes andother immune disorders is critical. VRI is committed to supporting importantresearch, like that being conducted by Dr. Greiner, to help expand the medicaluse of cord blood derived stem cells to include the treatment of additionaldiseases, including diabetes." "Our primary goal is to study the ability of these cord blood derived cells tomodulate a human immune system in a pre-clinical animal model," said Dale L.Greiner, Ph.D., professor of medicine, University of Massachusetts Mass MedicalSchool. "This collaboration between ViaCord and the University of MassachusettsMedical School is a great opportunity for interaction of the biomedical researchexpertise at the university with a global technology company dedicated humanhealth to fulfill the goals of bringing cutting edge research in the state tothe public." According to the American Diabetes Association, diabetes is the fifth leadingcause of death in the United States.

Type 1 diabetes, which accounts forbetween five and ten percent of all diagnosed cases of diabetes, is anautoimmune disease, generally occurring in children and young adults. Becausepatients with type 1 diabetes do not product insulin naturally, they must haveinsulin delivered by injection or a pump to help maintain their health There isno known way to prevent type 1 diabetes. About the University of Massachusetts Medical SchoolThe University of Massachusetts Medical School, one of the fastest growingacademic health centers in the country, has built a reputation as a world-classresearch institution, consistently producing noteworthy advances in clinical andbasic research. Thework of UMMS researcher Craig Mello, PhD, an investigator of the prestigiousHoward Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, thenof the Carnegie Institution of Washington, toward the discovery of RNAinterference was awarded the 2006 Nobel Prize in Physiology or Medicine and hasspawned a new and promising field of research, the global impact of which mayprove astounding. UMMS is the academic partner of UMass Memorial Health Care,the largest health care provider in Central Massachusetts. For more information,visit About PerkinElmer, Inc.PerkinElmer, Inc. is a global leader focused on improving the health and safetyof people and their environment.

The Company reported revenue of $1.8 billion in2007, has approximately 9,100 employees serving customers in more than 150countries, and is a component of the S&P 500 Index. Additional information isavailable through or 1-877-PKI-NYSE. About the ViaCord Research InstituteThe ViaCord Research Institute (VRI) is dedicated to developing and supportingscience, technology and medical treatments using cord blood stem cells whileleveraging comprehensive genetic information to facilitate the best treatmentoptions for families. For more info, visit Affecting Future PerformanceThis press release contains "forward-looking" statements within the meaning ofthe Private Securities Litigation Reform Act of 1995, including, but not limitedto, statements relating to estimates and projections of future earnings pershare, cash flow and revenue growth and other financial results, developmentsrelating to our customers and end-markets, and plans concerning businessdevelopment opportunities. A number of important risk factors could cause actual results todiffer materially from the results described, implied or projected in anyforward-looking statements. We disclaim any intention or obligation to update anyforward-looking statements as a result of developments occurring after the dateof this press release. Alfresco Web Studio delivers easy, user-driven site design, development, andcollaboration LONDON(Business Wire)Alfresco Software, Inc.